Who founded Abbratech Inc.?

Abbratech Inc. was founded by Michael Weiner.

Who are Abbratech Inc.'s investors?

Abbratech Inc.'s investors include Connecticut Innovations.

Where is Abbratech Inc. headquartered?

Abbratech Inc. is headquartered in Branford, US.

Abbratech Inc.

Branford, US · 1 known investors

Find your way into Abbratech Inc.

268 people in our graph share verified history with the Abbratech Inc. team — schools, employers, funds. One of them is your warm intro.

Mike Zakunlockedknows Michael Weiner · together at Cornell (overlapped)

×6knows the team · via Cornell

knows the team · via Encodia

knows the team · via Penn State University

knows the team · via GlaxoSmithKline

knows the team · via 454 Life Sciences

AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.

Biotech Deep Tech

Founders & leadership

Michael Weiner inFounderMichael Weiner holds a Ph.D. in Genetics from Cornell University and has founded multiple life sciences companies including Affomix, AxioMx, GnuBio, Encodia, and Abbratech, where he serves as Founder and CEO developing antibody discovery and engineering platform technologies. He has held senior scientific roles at 454 Life Sciences and RainDance Technologies, authored numerous peer-reviewed publications, holds multiple patents in genomics and proteomics, and has received substantial NIH and DARPA research funding.

Investors · 1

Connecticut InnovationsNew Haven · $500K – $2M

Competitors · 2

by search overlap

Abcam4 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.

Triple Ring Technologies3 shared keywords

Companies competing with Abbratech Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2023	$1.1M
National Institutes of Health (NIH)National Institutes of Health	Phase II	2023	$1.1M
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$296.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$295.5K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$339.1K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$253.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Abbratech Inc. - Connecticut Innovations Connecticut Innovationsctinnovations.com · Apr 2021

Frequently asked questions

What does Abbratech Inc. do?: AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.
Who founded Abbratech Inc.?: Abbratech Inc. was founded by Michael Weiner.
Who are Abbratech Inc.'s investors?: Abbratech Inc.'s investors include Connecticut Innovations.
Where is Abbratech Inc. headquartered?: Abbratech Inc. is headquartered in Branford, US.